Detalles de la búsqueda
1.
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
Ann Hepatol
; 16(3): 375-381, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28425407
2.
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
AIDS Care
; 28(3): 401-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26489045
3.
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lancet Gastroenterol Hepatol
; 5(10): 918-926, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32531259
4.
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
J Gastroenterol
; 54(1): 87-95, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30203225
5.
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Antiviral Res
; 158: 178-184, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120954
6.
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Hepatol Int
; 12(4): 356-367, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30030720
7.
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
AIDS
; 30(2): 251-9, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26684822
8.
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Patient
; 8(3): 257-67, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25808940
9.
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
AIDS
; 28(3): 335-44, 2014 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24670520
10.
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
AIDS
; 28(7): 989-97, 2014 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24508782
Resultados
1 -
10
de 10
1
Próxima >
>>